Low-Dose Ketamine for Anxiety Disorders article visual for Low Dose Ketamine

Editorial review

Educational content is reviewed for source quality, clinical boundaries, and readability. It is not medical advice; confirm care decisions with a licensed clinician.

Low dose ketamine for anxiety is an experimental, off-label treatment approach that may produce rapid symptom relief for some people with treatment-resistant anxiety conditions, but the evidence is still limited and it is not a first-line treatment. Research is most developed for obsessive-compulsive disorder, while evidence for generalized anxiety disorder and social anxiety disorder remains preliminary. Standard treatments such as cognitive behavioral therapy and SSRI or SNRI medication remain the usual starting point.

Anxiety disorders can be serious and persistent. According to the National Institute of Mental Health, an estimated 31.1 percent of U.S. adults experience an anxiety disorder at some point in their lives. People considering ketamine should discuss diagnosis, prior treatment response, medical history, medications, and substance use with a qualified clinician.

Quick Answer

Low-dose ketamine may reduce anxiety symptoms quickly in some research participants, particularly those whose symptoms have not improved with standard care. Its benefits can be short-lived, optimal repeat-treatment plans are unclear, and ketamine is not FDA-approved to treat anxiety disorders. It should be considered only with clinical screening, monitoring, and a plan for ongoing evidence-based care.

Why ketamine is being studied for anxiety

Ketamine is an NMDA receptor antagonist, meaning it changes signaling in the brain's glutamate system. Researchers are studying whether this action can affect neural circuits involved in threat processing, repetitive thoughts, and emotional regulation. Laboratory and clinical research also examines ketamine's relationship to synaptic plasticity, the brain's ability to form and adjust connections.

These mechanisms are hypotheses and research findings, not proof that ketamine corrects a single cause of anxiety. Anxiety disorders involve different symptoms, histories, and co-occurring conditions. A treatment decision should be based on the specific diagnosis and the treatments already tried.

What the research shows

Generalized anxiety disorder

A small dose-ranging study by Glue and colleagues reported reductions in anxiety ratings after subcutaneous ketamine among people with treatment-resistant generalized and social anxiety disorder. Effects occurred quickly, but the study was small and follow-up after a single dose was limited. The authors also reported transient dissociative effects at higher doses. This is useful early evidence, not a settled dosing standard.

Social anxiety disorder

Small studies suggest intravenous ketamine may reduce social anxiety symptoms for some participants in the days after treatment. The limited sample sizes and differing study designs make it difficult to determine who benefits, how long benefits last, or whether ketamine improves real-world social functioning beyond symptom scores.

Obsessive-compulsive disorder

Evidence for OCD includes a randomized crossover trial by Rodriguez and colleagues. In that study, a single intravenous ketamine infusion was associated with a rapid reduction in obsessive symptoms compared with saline placebo for some participants. The study was small, and compulsive behaviors may not respond in the same way as intrusive thoughts. Exposure and response prevention remains a core evidence-based OCD treatment.

A randomized trial indexed by PubMed reported that 50 percent of ketamine-treated participants with OCD met response criteria one week after a single infusion. That result came from a small study and should not be read as an expected outcome for every patient.

Reviews of ketamine for anxiety-spectrum conditions generally find a signal of short-term benefit, while also calling for larger controlled trials and clearer maintenance data. See the systematic review and meta-analysis indexed by PubMed for the limits of the current evidence base.

Compare low-dose options

Review routes, dosing discussions, and alternatives before speaking with a clinician.

Compare options

Potential advantages under clinical care

Some studies report symptom changes within hours or days rather than the weeks often needed to assess standard medication.
Ketamine has a different mechanism from SSRIs and SNRIs, which may be relevant when standard approaches have not helped.
Treatment may create an opportunity to engage in ongoing therapy when symptoms are severe.

Important limitations

Ketamine is not FDA-approved for anxiety disorders, and research does not establish a standard maintenance schedule.
Benefits after a single treatment may fade within days or weeks.
Dissociation, blood-pressure changes, nausea, and other adverse effects require screening and monitoring.
People with certain medical, psychiatric, or substance-use histories may not be appropriate candidates.

Safety, screening, and monitoring

Ketamine is FDA-approved as an anesthetic, not as a treatment for anxiety disorders. The FDA prescribing information for ketamine hydrochloride injection describes anesthesia use and important safety information, including cardiovascular and psychological effects that clinicians must consider.

During treatment, some people experience dissociation, altered perception, anxiety, nausea, dizziness, or temporary increases in blood pressure and heart rate. A calm setting, pre-treatment education, and post-treatment observation can help clinicians identify and manage acute effects. Read more about common ketamine side effects and cardiovascular monitoring.

Medication review matters. Benzodiazepines, alcohol, and other substances can affect safety, sedation, or treatment planning. Do not stop or change prescribed medication without the clinician managing it. Our guides on ketamine and benzodiazepines ketamine and alcohol safety risks, and potential drug interactions explain questions to raise before treatment.

Who may want to discuss this option

Low-dose ketamine may be worth discussing with a clinician for an adult with a diagnosed anxiety disorder who has had an adequate trial of evidence-based therapy, medication, or both and remains significantly symptomatic. It is not a substitute for urgent psychiatric care, crisis support, or a thorough diagnostic assessment.

It may be a poor fit, or require added specialist review, for people with uncontrolled cardiovascular disease, a history of psychosis or mania, active substance-use concerns, pregnancy or lactation considerations, or medical conditions that complicate monitoring. Individual suitability cannot be determined from an article.

Use ketamine as part of a longer-term plan

The most practical question is not simply whether ketamine can reduce symptoms quickly. It is what happens after the acute effect. A clinician may pair treatment with CBT, exposure-based therapy for social anxiety, or exposure and response prevention for OCD. The goal is to use any period of symptom relief to support skills, routines, and treatment engagement that can continue after the drug effect fades.

Learn how therapy may fit into care in our guide to ketamine integration therapy, and review monitoring and assessment considerations before discussing treatment.

Questions to bring to a clinical consultation

What is my diagnosis, and which evidence-based treatments have I tried at an adequate dose and duration?

What form of ketamine is being considered, and what evidence supports it for my specific condition?

How will my blood pressure, dissociation, sedation, and recovery be monitored?

How will my current medications, alcohol use, and substance-use history affect the plan?

What psychotherapy or follow-up plan will support improvement after treatment?

What signs would mean treatment should be paused, changed, or stopped?

Key Takeaway

Ketamine for anxiety is a developing clinical area, not an established replacement for CBT or first-line medication. The strongest next step is a careful evaluation that weighs limited evidence, short-term effects, safety monitoring, and a plan for ongoing treatment.